With reference to the stock exchange announcement from SoftOx Solutions AS
(SoftOx) on 2 July 2021, SoftOx has chosen to temporarily withdraw the
application. The biocidal products covered by the transitional arrangement will
not be affected, and a new application will be submitted by the deadline of 1
July 2022.  The transitional arrangement ensures the company's presence in the
market. The reason why the company chooses to withdraw the application is a
desire to rework and optimize the new application so that it better suits the
changed conditions that now apply.

When the application was first prepared, it was based on the Norwegian
Environment Agency's recommendations and guidelines, which have subsequently
proved to be unclear and not applicable, as well as the later lack of
coincidence between the Norwegian Environment Agency and the EU Commission's
interpretations in significant areas.

A new application will be submitted in accordance with the EU Biocidal
Regulations by 1 July 2022. The transitional arrangement is therefore valid if a
new application is submitted by this date.

Furthermore, SoftOx states that the products for surface disinfection have
received approval from the Norwegian Medicines Agency for use in the health care
system.

The company has started to deliver to Hospital Purchasing (HINAS) and other
players both within and outside the health sector.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com